post myocardial infarction

systematic review meta-analysis network meta-analysis

Select cholesterol lowering interventionanticoagulantantiplatelets drugantithromboticsanti inflammatory drugsantiarrythmic drugsantioxydantscalcium channel blockersomega-3 fatty acids primary prevention of sudden deathsecondary prevention All type of patient       acute and long term calcium blockersamiodaroneantiarryhtmicantioxydantaspirinclopidogreldietdipyridamolezetimibefibratesInterleukin-1ß inhibition long term calcium blockersomega-3 Fatty acidsoral anticoagulantoral direct thrombin inhibitorother cholesterol lowering drugsP2Y12 receptor-antagonistselective PAR-1 thrombin receptor antagoniststatinsstatins high dose atorvastatinpravastatinsimvastatinezetimibebezafibratediltiazemnifedipineverapamilamiodaroneaspirinAzimilideclopidogrelcoumadindabigatrandietdipyridamoldofetilidegemfibrozilmoricizineniacinticagrelorvorapaxarwarfarin vs placebo and controlvs placebo or controlvs antiplatelet drugsvs aspirinvs statin       early initiation

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (72)Non fatal MI (29)stroke (fatal and non fatal) (22)Cardiovascular death (21)Major bleeding (20)myocardial infarction (fatal and non fatal) (19)Coronary death (16)Coronary event (14)Minor bleeding (14)ischemic stroke (13)cardiac death (8)Revascularization (8)intracranial hemorrhage (8)Coronary death and non fatal MI (7)Death from cancer (7)cardiovascular events (7)Myopathy (6)Rhabdomyolysis (6)non cardiovascular death (6)Fatal MI (6)Arrhythmic/sudden death (5)Adverse events (4)MACE (4)Haemmorhagic stroke (4)new-onset diabetes (3)Fatal stroke (3)all cause death, MI, thrombo-embolic stroke (3)reinfarction (3)Fatal bleeding (3)cardiovascular death, MI, stroke (3)confirmed myocardial infarction (2)Cancer (1)Sudden death (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Non fatal MI
anti inflammatory drugs
not classified
CANTOS, 2017      NCT	canakinumab	placebo			Low risk of bias	remark
antiarrythmic drugs
not classified
BASIS, 1990	class I drugs	control				-
CAST I, 1991    NCT		placebo			Low risk of bias	-
Julian, 1982	d,l sotalol	placebo			Low risk of bias	-
amiodarone
Navarro-Lopez, 1993	early amiodarone	control				negative
BASIS, 1990	early amiodarone	control				suggesting
Hockings, 1987	early amiodarone	placebo			Low risk of bias	negative
Ceremuzynski, 1992	early amiodarone	placebo			Low risk of bias	negative
CAMIAT , 1991	early amiodarone	placebo			Low risk of bias	negative
Azimilide
ALIVE, 2004	azimilide	placebo			Low risk of bias	-
dofetilide
DIAMOND MI, 1997	dofetilide	placebo			Low risk of bias	-
moricizine
CAST II (late treatment), 1992	moricizine	placebo			Low risk of bias	-
CAST II (early treatment), 1992	moricizine	placebo			Low risk of bias	-
anticoagulant
not classified
Sixty Plus reinfarction Study, 1980	any anticoagulant	placebo			Low risk of bias	-
German-Austrian Study Group (oac vs pbo), 1980	phenprocoumon	placebo			Low risk of bias	negative
EPSIM, 1982	any anticoagulant	aspirin				negative
German-Austrian Study Group (oac vs asp), 1980	phenprocoumon	aspirin			Low risk of bias	negative
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin	control (on top of aspirin)				negative
ASPECT, 1994	coumadin	placebo			Low risk of bias	suggesting
ASPECT-2 (coumadin alone), 2002	coumadin	aspirin				suggesting
warfarin
CHAMP, 2002	warfarin	control (on top of aspirin)				negative
CARS (warafrin 3mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)			Risk of bias	suggesting
CARS (warfarin 1mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	negative
WARIS II (warfarin+ASA), 2002	warfarin	control (on top of aspirin)				suggesting
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)				negative
APRICOT-2, 2002	warfarin	control (on top of aspirin)				suggesting
WARIS, 1999	warfarin	control (on top of aspirin)			Low risk of bias	-
Williams, 1997	warfarin	placebo (on top of aspirin)			Low risk of bias	suggesting
WARIS II (warfarin alone), 2002	warfarin	aspirin				suggesting
antioxydants
not classified
ARISE, 2007      NCT	succinobucol	placebo			Low risk of bias	-
antiplatelets drug
aspirin
JAMIS, 1999	aspirin	placebo				suggesting
PARIS, 1980	aspirin	placebo			Low risk of bias	negative
GAMIS, 1980	aspirin	placebo			Low risk of bias	negative
AMIS, 1980    NCT	aspirin	placebo			Low risk of bias	suggesting
Vogel, 1979	aspirin	placebo			Low risk of bias	suggesting
CDPA, 1976	aspirin	placebo			Low risk of bias	negative
Cardiff I, 1974	aspirin	placebo			Low risk of bias	negative
Cardiff II, 1979	aspirin	placebo			Low risk of bias	negative
clopidogrel
CAPRIE, 1996	clopidogrel	aspirin			Low risk of bias	-
dipyridamol
PARIS, 1980	dipyridamol + aspirin	placebo			Low risk of bias	negative
PARIS-II, 1986	dipyridamol + aspirin	placebo			Low risk of bias	negative
PARIS, 1980	dipyridamol + aspirin	aspirin			Low risk of bias	negative
ticagrelor
PEGASUS 60mg, 2015        NCT	ticagrelor	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting
PEGASUS 90mg, 2015        NCT	ticagrelor	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting
vorapaxar
TRA-2P TIMI 50, 2012        NCT	vorapaxar	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting
antithrombotics
dabigatran
REDEEM, 2009    NCT	dabigatran	placebo			Low risk of bias	negative
calcium channel blockers
diltiazem
MDPIT, 1988	diltiazem	placebo			Low risk of bias	negative
nifedipine
MI study group, 1979	nifedipine					-
SPRINT I, 1988	nifedipine	placebo			Low risk of bias	negative
SPRINT II, 1993	nifedipine	placebo			Low risk of bias	negative
verapamil
DAVIT I, 1984	verapamil	placebo			Low risk of bias	-
DAVIT II, 1990	verapamil	placebo			Low risk of bias	negative
CRIS, 1996	verapamil	placebo			Low risk of bias	negative
Danish study, 1984	verapamil	placebo			Low risk of bias	negative
cholesterol lowering intervention
atorvastatin
TNT, 2005            NCT	atorvastatin high dose	atorvastatin	secondary prevention		Low risk of bias	conclusive
Vascular basis, 2005	atorvastatin high dose	lovastatin	secondary prevention		Exploratory	negative
SAGE, 2007	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	suggesting
REVERSAL, 2004	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	negative
IDEAL, 2005        NCT	atorvastatin high dose	simvastatin	secondary prevention		Risk of bias	suggesting
bezafibrate
BIP, 2000	bezafibrate	placebo	secondary prevention		Low risk of bias	negative
BECAIT, 1996	bezafibrate	placebo	secondary prevention		Exploratory	suggesting
diet
Tuttle, 2008	low fat diet	mediterranean-style diet			Risk of bias	-
ezetimibe
IMPROVE-IT, 2014      NCT	ezetimibe	placebo (on top statins)		early initiation	Low risk of bias	conclusive
gemfibrozil
VA-HIT, 1999      NCT	gemfibrozil	placebo			Low risk of bias	suggesting
niacin
Carlson (Stockholm), 1977	clofibtate+niacin	placebo	secondary prevention		Risk of bias	suggesting
pravastatin
CARE, 1996	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
LIPID, 1998	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
PACT, 2004	pravastatin	placebo	secondary prevention		Low risk of bias	negative
simvastatin
4S, 1994	simvastatin	placebo	secondary prevention		Low risk of bias	conclusive
omega-3 fatty acids
not classified
OMEGA, 2009      NCT	omega-3 Fatty acids	control			Risk of bias	negative
secondary prevention
aspirin
CDPA, 1976	aspirin	placebo			Low risk of bias	negative
Cardiff I, 1974	aspirin	placebo			Low risk of bias	negative
Vogel, 1979	aspirin	placebo			Low risk of bias	suggesting
AMIS, 1980    NCT	aspirin	placebo			Low risk of bias	suggesting
GAMIS, 1980	aspirin	placebo			Low risk of bias	negative
PARIS, 1980	aspirin	placebo			Low risk of bias	negative
JAMIS, 1999	aspirin	placebo				suggesting
Cardiff II, 1979	aspirin	placebo			Low risk of bias	negative
clopidogrel
CAPRIE, 1996	clopidogrel	aspirin			Low risk of bias	-
dipyridamol
PARIS, 1980	dipyridamol + aspirin	placebo			Low risk of bias	negative
PARIS-II, 1986	dipyridamol + aspirin	placebo			Low risk of bias	negative
PARIS, 1980	dipyridamol + aspirin	aspirin			Low risk of bias	negative